Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
about
Fluoroquinolone-resistant Streptococcus pneumoniae strains occur frequently in elderly patients in JapanLinezolid and vancomycin, alone and in combination with rifampin, compared with moxifloxacin against a multidrug-resistant and a vancomycin-tolerant Streptococcus pneumoniae strain in an in vitro pharmacodynamic model.Susceptibilities of Campylobacter jejuni isolates from Germany to ciprofloxacin, moxifloxacin, erythromycin, clindamycin, and tetracycline.Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 1: In vitro and animal models.Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 2: human trials.Levofloxacin for the treatment of community-acquired pneumonia.Bacterial Etiology and Antibiotic Resistance Profile of Community-Acquired Urinary Tract Infections in a Cameroonian City.Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy.Activities of moxifloxacin against, and emergence of resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model.In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus.Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model.In vivo efficacy of a new quinolone, DQ-113, against Streptococcus pneumoniae in a mouse model.Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacinSuboptimal ciprofloxacin dosing as a potential cause of decreased Pseudomonas aeruginosa susceptibility in children with cystic fibrosis.Linezolid, levofloxacin, and vancomycin against vancomycin-tolerant and fluoroquinolone-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic model.
P2860
Q34144100-99F5E95E-A24F-47ED-ABCA-64E9588F7D43Q35013754-EC58FEB3-1004-4B0B-931D-FA48D7299DE1Q35102717-FCA5EE1A-F49D-4890-87ED-66AA380A9F7CQ35201049-8AF296C4-D242-4B06-88A0-43CE86382ACCQ35547236-A2EBEED1-639C-4E08-8EE2-54AC6E553352Q36670872-3A464CF4-AF2A-463C-8389-B01D88047FDAQ37271146-BE43178D-6457-4C2B-BF54-947F54723286Q37733449-802FD2AB-99EA-4EEF-AA23-377EDE3B05F1Q39731788-D25DE22D-67BE-4246-9F0F-0C038B5A2ED2Q39746394-64E9C3B9-1F5A-4147-947C-DD066A68AEB9Q39792565-5A4370E1-2356-4751-897B-39127A37E1C6Q40345316-BC839A7D-E6DF-424C-847A-CE696C86237CQ42078632-3D781AAB-F429-4209-A872-8AFC569E416DQ42790860-F74926C8-4D74-4138-A57A-0038A8F263ECQ44705813-7B3C3F7D-688B-4F64-A1E2-187D3A551B49
P2860
Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Activities of newer fluoroquin ...... tant Streptococcus pneumoniae.
@ast
Activities of newer fluoroquin ...... tant Streptococcus pneumoniae.
@en
type
label
Activities of newer fluoroquin ...... tant Streptococcus pneumoniae.
@ast
Activities of newer fluoroquin ...... tant Streptococcus pneumoniae.
@en
prefLabel
Activities of newer fluoroquin ...... tant Streptococcus pneumoniae.
@ast
Activities of newer fluoroquin ...... tant Streptococcus pneumoniae.
@en
P2093
P2860
P1476
Activities of newer fluoroquin ...... tant Streptococcus pneumoniae.
@en
P2093
P2860
P304
P356
10.1128/AAC.45.6.1654-1659.2001
P407
P577
2001-06-01T00:00:00Z